ClinicalTrials.gg
Enrolling by invitationNCT05883748Updated Oct 9, 2026

HELIOS: Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Efficacy of DISC-1459 (Bitopertin) in Participants With EPP or XLP

A Phase 2/3 interventional study of DISC-1459 and DISC-1459 in Erythropoietic Protoporphyria, sponsored by Disc Medicine, Inc. Enrolling by invitation at 26 sites in 11 countries. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2026-10-09.

Sponsored by Disc Medicine, Inc · Phase 2/3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
230
Allocation
Randomized
Ages
12 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 18 studies in Protoporphyria, Erythropoietic with a site in United States — 4 open to participants now, 4 under way, 2 of them phase 3. Protoporphyria, Erythropoietic · United States.

Planned enrollment
Largest of 13
230 · median 77
Started
2023
with 1 other
Phase 2/3
3 of 18
2 open now
Registered
12th of 18
by date
Lead sponsor
4 of 18
Disc Medicine, Inc

Among the 18 studies in Protoporphyria, Erythropoietic with a site in United States, this one has the largest planned enrollment of the 13 interventional ones that give a count, is one of 2 that started in 2023, is one of 3 in phase 2/3, and was the 12th registered.

Protoporphyria, Erythropoietic

29 studies on the registry are indexed under Protoporphyria, Erythropoietic; 5 are open to participants now.

Browse Protoporphyria, Erythropoietic studies →

Open to participants now

4 of the 18 studies in Protoporphyria, Erythropoietic with a site in United States are open now. Recruiting first, the newest first:

All 4 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 3 Protoporphyria, Erythropoietic studies recruiting now, 3 set no upper age limit and none stop at 75 or younger; 3 take children under 18; none take healthy volunteers.

This study: 12 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 18 studies in Protoporphyria, Erythropoietic with a site in United States, or all of them as a file.
02

Study summary

This is an open-label, long-term extension study to investigate the safety, tolerability and efficacy of DISC-1459 in participants with EPP.

03

Conditions studied

  • Erythropoietic Protoporphyria

Keywords

  • EPP
  • DISC-1459
  • porphyria
  • RO4917838
04

Who can participate

Ages eligible
12 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants with diagnosis of EPP who are participating (or who have participated) in a prior Disc Medicine bitopertin study and who have completed the randomized treatment phase and End-of-Study visit
  • Aged ≥12 years upon study consent
  • Body weight ≥32 kg for participants \<18 years of age and ≥18.5 kg/m2 for adult participants
  • Willing to practice highly effective methods of (both males who have partners of and females of childbearing potential during the study, while taking study drug, and for at least 30 days after the last dose of study drug.
  • Negative urine or serum pregnancy test (females of childbearing potential).
  • Able to understand the study aims, procedures, and requirements, and provide written (and assent if necessary).
  • Able to comply with all study procedures.

Exclusion criteria

Exclusion Criteria:

  • Participants who have an ongoing SAE from a clinical study that is assessed by the investigator as related to bitopertin
  • Other medical or psychiatric condition or laboratory finding not specifically noted above that, in the judgement of the Investigator or Sponsor, would put the participant at unacceptable risk or otherwise preclude participation in the study
  • Condition or concomitant medication that would confound the ability to interpret clinical, clinical laboratory, or participant diary data, including a major psychiatric condition that has had an exacerbation or required hospitalization in the last 6 months
  • Planned treatment with afamelanotide or dersimelagon during the study
  • Planned use of any drugs or herbal remedies known to be strong inhibitors or inducers of cytochrome p450 (CYP)3A4 enzymes throughout the study
  • If female, pregnant, or breastfeeding
  • Participation in any other clinical protocol or trial, other than Disc Medicine bitopertin trials, that involves administration of experimental therapy and/or therapeutic devices within 30 days of Day 1
  • Score of PHQ-8 ≥10 at screening or imminent suicidal risk identified by the C-SSRS as defined as suicidal ideation with intent (Grade 4 or 5) within the last year or any suicidal behavior within the last 5 years.
  • Consumption of grapefruit/Seville orange and products containing these for 14 days prior to first dose of study drug and throughout the study
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
230 participants (estimated)

Study arms

  • Experimental
    DISC-1459 Oral Dose Level 1

    Oral dose, once a day

    Drug: DISC-1459

  • Experimental
    DISC-1459 Oral Dose Level 2

    Oral dose, once a day

    Drug: DISC-1459

Interventions

  • DISC-1459 dose level 1

    Also known as: Bitopertin, RO4917838

  • DISC-1459 dose level 2

    Also known as: Bitopertin, RO4917838

06

What researchers measure

Primary outcomes

  1. Incidence of treatment-emergent adverse events

    Time frame: up to 5 Years

  2. Incidence of clinically abnormal vital signs

    Time frame: up to 5 Years

  3. Incidence of clinically abnormal physical exam

    Time frame: up to 5 Years

  4. Incidence of abnormal laboratory test results

    Time frame: up to 5 Years

  5. Assessment of Patient Health Questionnaire (PHQ-8)

    The Patient Health Questionnaire (PHQ-8), an 8-item participant-report measure for screening for depression and for establishing depression severity. The total score ranges from 0-24, with a higher score indicating greater depression symptom severity.

    Time frame: up to 5 Years

  6. Assessment of C-SSRS

    The C-SSRS is a clinician-rated scale that assesses suicidality from ideation to behaviors and monitors the potential emergence of suicidality in clinical studies.

    Time frame: up to 5 Years

Secondary outcomes

  1. Change from baseline in daily daylight tolerance, as assessed by total hours spent in the sunlight without pain and average time to first prodromal syndrome in sunlight

    Time frame: up to 5 Years

  2. Change from baseline in whole blood metal-free PPIX levels

    Time frame: up to 5 Years

  3. Plasma Bitopertin Concentrations

    Time frame: up to 5 Years

07

Study locations

26 sites
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Aug 2023 (actual). Primary completion is estimated for Jun 2028, 58 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
May 22, 2023
First posted
Jun 1, 2023
StartActual
Aug 31, 2023
Primary completionEst.
Jun 2028
CompletionEst.
Jun 2028
Last update
Oct 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 9, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05883748
Lead sponsor
Disc Medicine, Inc
Responsible party
Sponsor
First posted
Jun 1, 2023
Start date
Aug 31, 2023
Primary completion
Jun 2028 (estimated)
Completion
Jun 2028 (estimated)
Last update
Oct 9, 2026

Study contacts

Will Savage, MD PhD
study director · Disc Medicine

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Bitopertin

Start the discussion